Based on this, the second generation of CAR-T cells had one co-stimulatory domain CD28, 4-1BB, ICOS or OX40 in the intracellular domain, which were significantly enhanced in the activation, proliferation, cytokine secretion and anti-tumor ability (6–8). This evidence concerns the gene CD28 and neoplasm.